# The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

> **NCT04371146** · NA · COMPLETED · sponsor: **University of Zurich** · enrollment: 120 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Methylphenidate
- **DRUG:** Reboxetine
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04371146
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-03
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-02-13
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371146, "The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04371146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*